Merck & Co., Inc: Hepatic Insufficiency trials

The registry lists 10 Hepatic Insufficiency studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)Not yet recruitingNCT05093972Phase 1
• A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)CompletedNCT06575959Phase 1Results posted
• Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)TerminatedNCT03295266Phase 1Results posted
• The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)CompletedNCT01797536Phase 1Results posted
• Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)CompletedNCT01512693Phase 1Results posted
• Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)CompletedNCT01043926Phase 1Results posted
• A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)CompletedNCT07049939Phase 1
• Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)CompletedNCT01114490Phase 1
• Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)CompletedNCT01043887Phase 1
• A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)CompletedNCT00696826Phase 1